The COVID-19 pandemic continues to have a serious impact on the lives of millions of
people worldwide. Empirical therapy is being used to reduce morbidity and mortality of …

Objective To evaluate whether favipiravir reduces the time to viral clearance as documented
by negative RT-PCR results for severe acute respiratory syndrome coronavirus 2 in mild …

The current coronavirus disease 2019 (COVID-19) outbreak caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in the wholesale market in …

Highlights What are the main findings? Favipiravir, an RNA-dependent RNA polymerase
inhibitor, shows no benefit in preventing the hospitalization of mild to moderate COVID-19 …

Due to the lack of an etiologic treatment for SARS-CoV-2 and the difficulties involved in
developing new drugs, some drugs already approved for other diseases or with efficacy …

ABSTRACT BACKGROUND: Favipiravir is generally used in treating coronavirus disease
2019 (COVID-19) pneumonia in Turkey. OBJECTIVE: To determine the side effects of …

Background Although more than a year past since COVID-19 was defined, there is no
specific treatment yet. Since COVID-19 management differs over time, it is hard to determine …

Favipiravir is a potential antiviral drug undergoing clinical trials to manage various viral
infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …

This study aimed to evaluate the efficacy of favipiravir (FPV) in preventing the development
of severe COVID-19 in patients with mild-to-moderate symptoms. The study evaluated 1037 …

After concerns were brought to the Editors' attention after publication, the raw data
underlying the study were requested. The authors provided several versions of their dataset …